Cassava Sciences (SAVA) Stock Price, News & Analysis

Company Overview

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Key Stats

• Today's Range: $2.61 to $2.77
• 50-Day Range: $2.29 to $32.06
• 52-Week Range: $2.23 to $42.20
• Volume: 1.56 million shs
• Average Volume: 3.17 million shs
• Market Capitalization: $126.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $111.50
• Consensus Rating: Moderate Buy

Cassava Sciences Stock Analysis - MarketRank™

Cassava Sciences scored higher than 89% of companies evaluated by MarketBeat, and ranked 122nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cassava Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cassava Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cassava Sciences are expected to grow in the coming year, from ($3.97) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cassava Sciences is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cassava Sciences is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cassava Sciences has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

34.57% of the outstanding shares of Cassava Sciences have been sold short.

Short Interest Ratio / Days to Cover

Cassava Sciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cassava Sciences has recently decreased by 5.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cassava Sciences does not currently pay a dividend.

Dividend Growth

Cassava Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.82

Percentage of Shares Shorted

34.57% of the outstanding shares of Cassava Sciences have been sold short.

Short Interest Ratio / Days to Cover

Cassava Sciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cassava Sciences has recently decreased by 5.62%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.04

News Sentiment

Cassava Sciences has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Cassava Sciences this week, compared to 8 articles on an average week.

Search Interest

Only 32 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.

MarketBeat Follows

Only 32 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -3% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cassava Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $246,308.00 in company stock.

Percentage Held by Insiders

12.20% of the stock of Cassava Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 38.05% of the stock of Cassava Sciences is held by institutions.

SAVA Stock Analysis - Frequently Asked Questions

How have SAVA shares performed this year?

Cassava Sciences' stock was trading at $2.36 at the beginning of the year. Since then, SAVA shares have increased by 11.0% and is now trading at $2.62.
View the best growth stocks for 2025 here.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) issued its earnings results on Thursday, November, 7th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.79.

When did Cassava Sciences' stock split?

Cassava Sciences shares split before market open on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were distributed to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.

Who are Cassava Sciences' major shareholders?

Top institutional shareholders of Cassava Sciences include SG Americas Securities LLC (0.03%). Insiders that own company stock include Eric Schoen and James William Kupiec.
View institutional ownership trends.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 2/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SAVA
• CUSIP: N/A
• CIK: 1069530
• Web: www.cassavasciences.com
• Phone: (512) 501-2444
• Fax: 512-501-0414
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $111.50
• High Stock Price Target: $116.00
• Low Stock Price Target: $107.00
• Potential Upside/Downside: +4,155.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-97,220,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -88.05%
• Return on Assets: -64.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.55
• Quick Ratio: 3.55

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.26 per share
• Price / Book: 0.80

Miscellaneous

• Outstanding Shares: 48,110,000
• Free Float: 42,241,000
• Market Cap: $126.05 million
• Optionable: Optionable
• Beta: -0.99